Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32622449.
- Also identified by DOI 10.1016/j.mayocp.2020.05.006 and PMC identifier 7236707.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Obesity has reached epidemic proportions in the United States and in much of the westernized world, contributing to considerable morbidity. Several of these obesity-related morbidities are associated with greater risk for death with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 penetrates human cells through direct binding with angiotensin-converting enzyme 2 receptors on the cell surface. Angiotensin-converting enzyme 2 expression in adipose tissue is higher than that in lung tissue, which means that adipose tissue may be vulnerable to COVID-19 infection. Obese patients also have worse outcomes with COVID-19 infection, including respiratory failure, need for mechanical ventilation, and higher mortality. Clinicians need to be more aggressive when treating obese, especially severely obese, patients with COVID-19 infection.
Medical subject headings
- Betacoronavirus
- Coronavirus Infections
- Obesity
- Pneumonia, Viral